Geode Capital Management LLC Increases Stake in Pfizer Inc. (PFE)

Geode Capital Management LLC lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 63,123,777 shares of the biopharmaceutical company’s stock after acquiring an additional 1,881,570 shares during the period. Pfizer accounts for about 0.8% of Geode Capital Management LLC’s holdings, making the stock its 18th biggest position. Geode Capital Management LLC owned approximately 1.06% of Pfizer worth $2,281,563,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in the company. First Dallas Securities Inc. acquired a new stake in shares of Pfizer during the fourth quarter worth $118,000. Americafirst Capital Management LLC acquired a new stake in shares of Pfizer during the third quarter worth $127,000. Delphi Private Advisors LLC lifted its holdings in shares of Pfizer by 84.3% during the fourth quarter. Delphi Private Advisors LLC now owns 3,499 shares of the biopharmaceutical company’s stock worth $127,000 after purchasing an additional 1,600 shares during the period. Oak Point Wealth Management acquired a new stake in shares of Pfizer during the fourth quarter worth $165,000. Finally, Cerebellum GP LLC acquired a new stake in shares of Pfizer during the fourth quarter worth $166,000. Institutional investors and hedge funds own 69.53% of the company’s stock.

In other news, insider Kirsten Lund-Jurgensen sold 9,510 shares of the firm’s stock in a transaction on Monday, February 26th. The stock was sold at an average price of $37.19, for a total value of $353,676.90. Following the completion of the transaction, the insider now owns 36,959 shares in the company, valued at $1,374,505.21. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Ian C. Read sold 132,312 shares of the firm’s stock in a transaction on Tuesday, May 1st. The shares were sold at an average price of $36.01, for a total value of $4,764,555.12. The disclosure for this sale can be found here. In the last 90 days, insiders sold 380,349 shares of company stock valued at $13,829,340. Company insiders own 0.06% of the company’s stock.



Several equities research analysts recently weighed in on PFE shares. Morningstar set a $38.00 price target on Pfizer and gave the stock a “neutral” rating in a report on Tuesday, January 30th. Credit Suisse Group reaffirmed a “neutral” rating and set a $39.00 price target on shares of Pfizer in a report on Friday, May 18th. Barclays downgraded Pfizer from an “overweight” rating to an “equal weight” rating and decreased their price target for the stock from $41.00 to $38.00 in a report on Thursday, April 5th. UBS set a $42.00 price target on Pfizer and gave the stock a “buy” rating in a report on Wednesday, January 31st. Finally, ValuEngine downgraded Pfizer from a “buy” rating to a “hold” rating in a report on Wednesday, May 2nd. Three investment analysts have rated the stock with a sell rating, twelve have assigned a hold rating and nine have assigned a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $40.08.

Pfizer opened at $35.68 on Friday, MarketBeat Ratings reports. Pfizer Inc. has a one year low of $31.67 and a one year high of $39.43. The firm has a market capitalization of $214.12 billion, a price-to-earnings ratio of 13.46, a price-to-earnings-growth ratio of 1.79 and a beta of 0.89. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.27 and a quick ratio of 0.98.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 1st. The biopharmaceutical company reported $0.77 earnings per share for the quarter, beating analysts’ consensus estimates of $0.74 by $0.03. Pfizer had a return on equity of 25.29% and a net margin of 41.29%. The business had revenue of $12.91 billion during the quarter, compared to analysts’ expectations of $13.14 billion. During the same quarter last year, the business posted $0.69 earnings per share. The business’s revenue for the quarter was up 1.0% on a year-over-year basis. analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

The company also recently declared a quarterly dividend, which will be paid on Friday, June 1st. Stockholders of record on Friday, May 11th will be given a $0.34 dividend. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.81%. The ex-dividend date is Thursday, May 10th. Pfizer’s dividend payout ratio is currently 51.32%.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply